Kiyuk Chang

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial

Seung‐Jung Park, Jung‐Min Ahn, Do‐Yoon Kang et al. · The Lancet · 2024 · 212 citations

Percutaneous Coronary Intervention, Optimal Medical Therapy, Cardiovascular Disease +8

Infarcted Myocardium-Primed Dendritic Cells Improve Remodeling and Cardiac Function After Myocardial Infarction by Modulating the Regulatory T Cell and Macrophage Polarization

Eun Ho Choo, Jun‐Ho Lee, Eunhye Park et al. · Circulation · 2017 · 178 citations

Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial

Chan Joon Kim, Mahn‐Won Park, Min Chul Kim et al. · The Lancet · 2021 · 177 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +12